Cargando…

Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study

Background: Health technology assessment (HTA) has increased in importance in supporting payer decision making by assessing the relative effectiveness and cost effectiveness of new medicines. Thus, pharmaceutical companies need to address the HTA requirements early during development to improve reim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ting, McAuslane, Neil, Liberti, Lawrence, Gardarsdottir, Helga, Goettsch, Wim, Leufkens, Hubert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775670/ https://www.ncbi.nlm.nih.gov/pubmed/33390978 http://dx.doi.org/10.3389/fphar.2020.594549

Ejemplares similares

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
por: Rodier, Céline, et al.
Publicado: (2020)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017)

Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation
por: Bujar, Magdalena, et al.
Publicado: (2020)

The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions
por: Bujar, Magdalena, et al.
Publicado: (2021)

Enabling appropriate use of antibiotics: review of European Union procedures of harmonising product information, 2007 to 2020
por: Opalska, Aleksandra, et al.
Publicado: (2020)

Health, social and legal supports for migrant agricultural workers in France, Italy, Spain, Germany, Canada, Australia and New Zealand: a scoping review
por: Caxaj, C. Susana, et al.
Publicado: (2023)

An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017–2018 using the OpERA methodology
por: Liberti, Lawrence, et al.
Publicado: (2020)

To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016
por: Kühler, Thomas Christian, et al.
Publicado: (2019)

Cancer Organizations in France, Belgium, England, Germany and Sweden
por: Spies, John W.
Publicado: (1931)

Responding to measles outbreaks in underserved Roma and Romanian populations in England: the critical role of community understanding and engagement
por: Bell, Sadie, et al.
Publicado: (2020)

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
por: Alsamil, Ali M., et al.
Publicado: (2021)

France at CERN : visit of companies
Publicado: (1997)

Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom
por: DiBonaventura, Marco daCosta, et al.
Publicado: (2013)

The Reliability and Relevance of a Quality of Decision Making Instrument, Quality of Decision-Making Orientation Scheme (QoDoS), for Use During the Lifecycle of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2019)

A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines
por: Bujar, Magdalena, et al.
Publicado: (2020)

Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
por: Bujar, Magdalena, et al.
Publicado: (2017)

Preparing for the upcoming 2022/23 influenza season: A modelling study of the susceptible population in Australia, France, Germany, Italy, Spain and the United Kingdom
por: Boudewijns, Bronke, et al.
Publicado: (2022)

Modelling the initial epidemic trends of COVID-19 in Italy, Spain, Germany, and France
por: Wang, Kai, et al.
Publicado: (2020)

Development of trauma systems in Europe—reports from England, Germany, the Netherlands, and Spain
por: Chesser, Tim JS, et al.
Publicado: (2023)

Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada
por: Smith-Palmer, J., et al.
Publicado: (2019)

A New Practical Formulary of Hospitals of England, Scotland, Ireland, France, Germany, &c.
Publicado: (1836)

Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF‐α Inhibitors
por: Minnema, Lotte A., et al.
Publicado: (2020)

A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013–2016
por: Patel, Prisha, et al.
Publicado: (2020)

Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study
por: Minnema, Lotte A., et al.
Publicado: (2019)

Are Further Interventions Needed to Prevent and Manage Hospital-Acquired Hyponatraemia? A Nationwide Cross-Sectional Survey of IV Fluid Prescribing Practices
por: Sindahl, Per, et al.
Publicado: (2020)

Travels in France and England
Publicado: (1807)

Implementation of a Framework for an Abridged Review Using Good Reliance Practices: Optimising the Medicine Regulatory Review Process in South Africa
por: Keyter, Andrea, et al.
Publicado: (2020)

Construction projects in Belgium, the Czech Republic, France, Germany, the Netherlands, Spain and Sweden: the legal framework
por: Alliance of European Lawyers. Brussels
Publicado: (1997)

Data on Income inequality in Germany, France, Italy, Spain, the UK, and other affluent nations, 2012
por: Dorling, Danny
Publicado: (2015)

How target-orientated is the use of homeopathy in dairy farming?—A survey in France, Germany and Spain
por: Keller, Diana, et al.
Publicado: (2019)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Post‐marketing dosing changes in the label of biologicals
por: Minnema, Lotte A., et al.
Publicado: (2019)

Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities
por: McAuslane, Neil, et al.
Publicado: (2023)

The Incidence, Prevalence, and Mortality of Stroke in France, Germany, Italy, Spain, the UK, and the US: A Literature Review
por: Zhang, Younan, et al.
Publicado: (2012)

Ten-Year Trends in Sales of Alzheimer Disease Drugs in France Compared With Sales in Germany, Spain, and the UK
por: Ben Hassen, Céline, et al.
Publicado: (2022)

Use of Real‐World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018–2019
por: Eskola, Sini Marika, et al.
Publicado: (2021)

A Comparison of Hospital Area Measurement in Germany, Canada, Australia, and the United States: Part 1
por: Viergutz, Hannah-Kathrin Silja, et al.
Publicado: (2022)

Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_asgjdsf8mpo72q12eo49019rcd